Compare ABAT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABAT | TLSI |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 302.3M | 250.0M |
| IPO Year | 2013 | 2020 |
| Metric | ABAT | TLSI |
|---|---|---|
| Price | $1.34 | $3.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.00 | ★ $10.40 |
| AVG Volume (30 Days) | ★ 2.5M | 206.3K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $45,151,000.00 |
| Revenue This Year | $45.86 | $17.65 |
| Revenue Next Year | N/A | $40.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $1.37 | $2.20 |
| 52 Week High | $6.01 | $7.95 |
| Indicator | ABAT | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 18.60 | 30.66 |
| Support Level | N/A | $3.05 |
| Resistance Level | $2.41 | $3.68 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 1.32 | 7.07 |
American Battery Technology Co is an integrated critical battery minerals company that develops technologies for both primary battery minerals manufacturing and lithium-ion battery recycling. It operates battery recycling facilities that process materials from electric vehicle batteries, stationary battery energy storage systems, and consumer electronics. The company also advances lithium production projects using proprietary technology to produce battery-grade lithium hydroxide. It generates revenue mainly from its recycling operations and is expanding capacity with strategic partnerships and government grants. The company focuses on creating a closed-loop battery materials supply chain to support sustainable manufacturing in the United States.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.